公开(公告)号：US10072082B2

公开(公告)日：2018-09-11

申请号：US14950748

申请日：2015-11-24

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US09856320B2

公开(公告)日：2018-01-02

申请号：US14400667

申请日：2013-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok Kumar Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.